Independently of their efficacy as therapeutic agents in the canine model, AKT1, SYK and BTK expression is consistent between B-cell lymphomas and B-cell-derived cell lines as well as between probable T-cell lymphomas and T-cell-derived cell lines, indicating the suitability of the cell lines to evaluate AKT1, SYK and BTK inhibitors. The gene discussed is SYK; the disease is B-cell non-Hodgkin lymphoma.